Core Insights - aTyr Pharma, Inc. has appointed Eric Benevich to its Board of Directors, effective December 10, 2024, to support its commercialization efforts [1][2] - Mr. Benevich brings over 30 years of commercial experience in the pharmaceutical industry, having held significant roles at various biopharmaceutical companies [2] - aTyr is focused on developing first-in-class medicines from its proprietary tRNA synthetase platform, with its lead candidate being efzofitimod for treating interstitial lung disease [3] Company Overview - aTyr Pharma is a clinical stage biotechnology company that utilizes evolutionary intelligence to develop therapies targeting fibrosis and inflammation [3] - The company’s discovery platform aims to identify therapeutic intervention points by exploring signaling pathways from its library of tRNA synthetase-derived domains [3] - The lead therapeutic candidate, efzofitimod, is an immunomodulator currently in clinical development for immune-mediated disorders affecting the lungs [3]
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors